Accutane Risk Management Program Changes Held Up By Celgene Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
Four patents relating to the STEPS risk management program for Thalomid are an “obstacle” to implementing an augmented isotretinoin program, FDA says. The agency’s Office of Chief Counsel is reviewing the issue.